Resimac Group Limited (ASX:RMC)
Australia
· Delayed Price · Currency is AUD | Market Cap | 355.76M |
| Revenue (ttm) | 195.86M |
| Net Income (ttm) | 49.51M |
| Shares Out | 395.28M |
| EPS (ttm) | 0.12 |
| PE Ratio | 7.24 |
| Forward PE | 6.48 |
| Dividend | 0.07 (7.78%) |
| Ex-Dividend Date | Mar 6, 2026 |
| Volume | 31,605 |
| Average Volume | 103,822 |
| Open | 0.905 |
| Previous Close | 0.900 |
| Day's Range | 0.900 - 0.910 |
| 52-Week Range | 0.810 - 1.225 |
| Beta | 1.44 |
| RSI | 41.89 |
| Earnings Date | May 26, 2026 |
About Resimac Group
Resimac Group Limited provides residential mortgage and asset finance lending products in Australia and New Zealand. The company operates through Home Loan Lending business, New Zealand Lending, and Asset Finance Lending segments. It offers prime and specialist lending products; SME/commercial finance products; and home, equipment, secured, novated leasing, and car loans. It also provides mortgage originator and trustee, lender, mortgage manager and broker, consumer and commercial lending, managed investment trust, and LMI captive insurer servi... [Read more]
Financial Performance
In fiscal year 2025, Resimac Group's revenue was 163.59 million, an increase of 11.08% compared to the previous year's 147.27 million. Earnings were 34.58 million, a decrease of -0.02%.
Financial StatementsNews
Resimac Group Ltd (ASX:RMC) Full Year 2025 Earnings Call Highlights: Strategic Growth and ...
Resimac Group Ltd (ASX:RMC) Full Year 2025 Earnings Call Highlights: Strategic Growth and Shareholder Returns
ASX 200 LIVE: Mayne Pharma shares plunge; CBA hits record; JHX sales, earnings slip amid AZEK buy; ASIC sues Resimac, sharemarket rises
Shares lift; CBA resets intraday record, tops $176; Mayne Pharma-Cosette tie-up hangs in balance; Nufarm plunges; James Hardie drops 5pc. Follow live.